HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Lowers Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on Cogent Biosciences (NASDAQ:COGT) but has lowered the price target from $27 to $13.

December 15, 2023 | 11:34 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cogent Biosciences' price target has been reduced from $27 to $13 by HC Wainwright & Co., although the Buy rating is maintained.
The reduction in price target by HC Wainwright & Co. could lead to a negative short-term sentiment among investors, as it suggests a lower valuation expectation for Cogent Biosciences. However, the maintenance of a Buy rating indicates the analyst still sees long-term value in the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100